Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

X-rays yield mechanism of alzheimer's drug

Weizmann Institute Of Science : 24 February, 2003  (Company News)
A team of Weizmann scientists has gained new insight into the effects of a newly approved drug, rivastigmine, in treating Alzheimer's disease, a debilitating brain disease causing memory loss in around 10% of the elderly. The study was published in the American Chemical Society journal Biochemistry.
A team of Weizmann scientists has gained new insight into the effects of a newly approved drug, rivastigmine, in treating Alzheimer's disease, a debilitating brain disease causing memory loss in around 10% of the elderly. The study was published in the American Chemical Society journal Biochemistry.

'The results were surprising,' says Prof. Joel Sussman, of the Structural Biology Department.

'They show that we can safely treat Alzheimer's disease with much lower quantities of rivastigmine, thus minimizing unwanted adverse effects.'

The drug, currently sold as ExelonTM, helps slow memory loss of Alzheimer patients. However, its mechanism of action at the molecular level had not been studied prior to this research, which was conducted by Sussman, Prof. Israel Silman of the Neurobiology Department, and Ph.D. student Pazit Bar-on.

Alzheimer's disease involves deterioration of nerve cells releasing a substance called acetylcholine, which carries messages between brain cells. The lack of acetylcholine in Alzheimer's patients is compoun-ded by the action of an enzyme called acetylcholinesterase, which rapidly breaks down acetylcholine. The desired effect of Alzheimer drugs like rivastigmine is to inhibit AChE long enough to adequately raise the levels of acetylcholine.

'We wanted to see how long it takes AChEs to return to normal, or become 'reactivated,' after inhibition by the drug,' says Silman. Testing rivastigmine on various types of AChE (extracted from an electric ray, the fruit fly and humans), the team was surprised to find that inhibition was almost irreversible, with little reactivation over a period of days.

To explain this at the molecular level, the scientists took snapshots of rivastigmine bound to AChE by projecting X-rays onto crystals of rivastigmine combined with AChE, and observing the X-rays' diffraction patterns. They then built a molecular map showing the spatial arrangement of all the atoms of AChE and rivastigmine.

Using these maps, the scientists found why the inhibition of AChE by the drug is nearly irreversible: after binding to AChE, rivastigmine breaks in two and moves some of AChE's atoms, making it difficult for it to return to an active state.

The maps provide important information for designing novel chemicals that might fight Alzheimer's more effectively and with less side effects.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo